Quince Therapeutics, Inc. (QNCX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quince Therapeutics, Inc. (QNCX) has a cash flow conversion efficiency ratio of -9.375x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.93 Million) by net assets ($1.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Quince Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Quince Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Quince Therapeutics, Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Quince Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quince Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strategic Energy Resources Ltd
AU:SER
|
-0.024x |
|
Bioatla Inc
NASDAQ:BCAB
|
0.316x |
|
Trainline Plc
LSE:TRN
|
0.441x |
|
elumeo SE
XETRA:ELB
|
0.087x |
|
Sarthak Metals Limited
NSE:SMLT
|
0.009x |
|
Concord Medical Services Holdings
NYSE:CCM
|
0.009x |
|
Patria Private Equity Trust
LSE:PPET
|
-0.001x |
|
Walker River Resources Corp.
V:WRR
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Quince Therapeutics, Inc. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Quince Therapeutics, Inc. from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Quince Therapeutics, Inc. (QNCX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $30.15 Million | $-31.90 Million | -1.058x | -392.27% |
| 2023-12-31 | $85.08 Million | $-18.29 Million | -0.215x | +50.89% |
| 2022-12-31 | $100.59 Million | $-44.04 Million | -0.438x | +17.51% |
| 2021-12-31 | $118.59 Million | $-62.93 Million | -0.531x | -79.89% |
| 2020-12-31 | $172.26 Million | $-50.82 Million | -0.295x | -2.37% |
| 2019-12-31 | $115.48 Million | $-33.28 Million | -0.288x | -75.98% |
| 2018-12-31 | $71.42 Million | $-11.70 Million | -0.164x | -133.79% |
| 2017-12-31 | $-20.28 Million | $-9.83 Million | 0.485x | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mut… Read more